Connect with SHL at Drug Delivery Partnerships 2018
SHL is exhibiting at the 2018 Drug Delivery Partnerships (DDP) conference in Florida from January 22-24 to present its innovative drug delivery devices and its commercialization solutions for final assembly, labeling, and packaging.
“DDP is an event that has for the past two decades been an important meeting place for drug delivery leaders. With the increased use of biologic and biosimilar formulations to treat chronic indications, SHL’s safe and reliable self-injection offerings meet the industry’s demand for efficient drug delivery devices that are designed to improve treatment outcomes,” said Jamie Gould, Manager of Business Development at SHL Group.
During the event, SHL will introduce the groundbreaking Maggie®, a two-step cartridge-based autoinjector for high-volume injections built with SHL’s market-proven Needle Isolation Technology (NIT®). Also on display is Bertha®, a versatile autoinjector that can accommodate a wide range of fill volumes and viscosities.
SHL will also present its Molly® 2.25 autoinjector. Designed with the same robust features as the classic Molly® family of preconfigured devices, this high-volume variation is equally safe and intuitive, and offers the same flexibility and short development timelines for faster commercialization.
To find out more about SHL’s latest innovations and comprehensive solutions for device commercialization, visit Booth 301 at the PGA National Resort & Spa in Palm Beach Gardens, Florida.
